


CLAIMS

1. A composition comprising a salt of a compound represented by Formula (I):



wherein:

R^1 , R^2 , and R^3 are each independently H or substituted or unsubstituted alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclyl, or heterocyclalkyl;

R^4 , independently for each occurrence, is selected from substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclyl, oxo, $-OR^b$, $-CH_2OR^b$, halo, hydroxyl, and hydroxyalkyl;


R^b is substituted or unsubstituted alkyl, aryl, arylalkyl, or heterocyclyl;

p is 0, 1, or 2;

R^6 is hydrogen or substituted or unsubstituted alkyl; and

R^7 , R^8 , and R^9 are each independently hydrogen or alkyl;

wherein the compound is not:



~~preferably wherein the compound comprises at least one D-amino acid residue at least 90% of the compound in the composition is present as the salt.~~

2. The salt composition of claim 1, wherein:

R^1 , R^2 , and R^3 are each independently H or substituted or unsubstituted alkyl, arylalkyl, or heterocyclalkyl;

R^4 , independently for each occurrence, is selected from substituted or unsubstituted alkyl, oxo, hydroxyl, $-OR^b$, hydroxyalkyl, $-CH_2OR^b$, and halo;

R^b is substituted or unsubstituted alkyl, aryl, arylalkyl, or heterocyclyl;

R⁶ is hydrogen or substituted or unsubstituted alkyl; and
R⁷, R⁸, and R⁹ are each independently hydrogen or alkyl.

3. The salt composition of claim 1 or 2, wherein, where indicated, alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclyl, or heterocyclylalkyl is unsubstituted or is substituted with one or more substituents selected from halo, haloalkyl, oxo, -CN, -NO₂, =N-OH, -N₃, -R^a, -OR^a, -SR^a, -N(R^a)₂, -N(R^a)₃⁺, =NR^a, -NHC(=O)R^c, -C(=O)R^c, -C(=O)N(R^a)₂, -S(=O)₂R^c, -OS(=O)₂OR^a, -S(=O)₂OR^a, -S(=O)₂N(R^a)₂, -S(=O)R^c, -OP(=O)(OR^a)₂, -(alkylene)-C(=O)R^c, -C(=S)R^c, -C(=O)OR^a, -(alkylene)-C(=O)OR^a, -C(=S)OR^a, -C(=O)SR^a, -C(=S)SR^a, -(alkylene)-C(=O)N(R^a)₂, -C(=S)N(R^a)₂, and -C(-NR^a)N(R^a)₂;

R^a, independently for each occurrence, is hydrogen, or substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl, or cycloalkylalkyl(~~cycloalkyl~~)alkyl; and



R^c, independently for each occurrence, is substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl, or cycloalkylalkyl(~~cycloalkyl~~)alkyl.

4. The salt composition of any one of claims 1-3, wherein, where indicated, alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclyl, or heterocyclylalkyl is unsubstituted or is substituted with one or more substituents selected from halo, haloalkyl, oxo, -R^a, -OR^a, -N(R^a)₂, -N(R^a)₃⁺, -NHC(=O)R^c, -C(=O)R^c, -C(=O)N(R^a)₂, -C(=O)OR^a, -(alkylene)-C(=O)OR^a, and -(alkylene)-C(=O)N(R^a)₂;


R^a, independently for each occurrence, is hydrogen, or substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl, or cycloalkylalkyl(~~cycloalkyl~~)alkyl; and

R^c, independently for each occurrence, is substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl, or cycloalkylalkyl(~~cycloalkyl~~)alkyl.


5. The ~~salt composition~~ of any one of claims 1-4, wherein R¹ is selected from



R² is selected from , , , , , , , ,




R³ is selected from



p is 1 or 2; and R⁴, independently for each occurrence, is selected from -CH₃, halo, hydroxyl, ~~and~~ hydroxyalkyl, and oxo; and/or

R⁴ is oxo; and/or



R⁷ is (C₁-C₁₀)alkyl; and/or




R⁸ is -CH₃ or -H; and/or






R⁹ is -CH₃ or -H.






6. The composition of any one of claims 1-5, wherein the compound comprises at least one D-amino acid residue.



67. The salt composition of any one of claims 1-56, wherein the compound comprises at least two, at least three, at least four, at least five, at least six, at least seven, or at least eight D-amino acid residues.

78. The salt composition of claim 1, wherein the compound is selected from the following:
























89. The salt composition of claim 1, wherein the compound is selected from the following:












910. The salt composition of claim 1, wherein the compound is selected from the following:




Hyp (2*S*,4*R*) Gly Gln Leu Gly Leu Ala Gly Pro Gln








Hyp (2*S*,4*R*) Gly Gln Leu Gly Leu Ala Gly Pro Nle(6-OH)









Hyp (2*S*,4*S*) Gly Gln Leu Gly Leu Ala Gly Pro Lys







(4-oxo)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys














1011. The salt composition of claim 1, wherein the compound is selected from the following:






112. The salt composition of claim 1, wherein the compound is selected from the following:



4213. A compound represented by Formula (I):



or a pharmaceutically acceptable salt thereof;

wherein:

R^1 , R^2 , and R^3 are each independently H or substituted or unsubstituted alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclyl, or heterocyclalkyl;

R^4 , independently for each occurrence, is selected from substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclyl, oxo, $-OR^b$, $-CH_2OR^b$, halo, hydroxyl, and hydroxyalkyl;

R^b is substituted or unsubstituted alkyl, aryl, arylalkyl, or heterocyclyl;

p is 0, 1, or 2;

R^6 is hydrogen or substituted or unsubstituted alkyl; and

R^7 , R^8 , and R^9 are each independently hydrogen or alkyl;

wherein at least one of:

(a) at least one of R^1 , R^2 , and R^3 is substituted or unsubstituted (C_2-C_{10}) haloalkyl;

(b) at least one of alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclyl, or heterocyclalkyl is substituted with one or more substituents selected from $-R^a$, $-OR^a$, $-SR^a$, $-N(R^a)_2$, $-N(R^a)_3^+$, $=NR^a$, $-NHC(=O)R^c$, $-C(=O)R^c$, $-C(=O)N(R^a)_2$, $-S(=O)_2R^c$, $-OS(=O)_2OR^a$, $-S(=O)_2OR^a$, $-S(=O)_2N(R^a)_2$, $-S(=O)R^c$, $-OP(=O)(OR^a)_2$, $-(alkylene)-C(=O)R^c$, $-C(=S)R^c$, $-C(=O)OR^a$, $-(alkylene)-C(=O)OR^a$, $-C(=S)OR^a$, $-C(=O)SR^a$, $-C(=S)SR^a$, $-(alkylene)-C(=O)N(R^a)_2$, $-C(=S)N(R^a)_2$, and $-C(-NR^a)N(R^a)_2$; and

~~at least one occurrence of R^a or~~ at least one occurrence of R^a and R^c is are each independently heterocyclalkyl, cycloalkyl, or cycloalkylalkyl(cycloalkyl)alkyl;

(c) the compound comprises at least one D-amino acid residue; or



(d) at least two occurrences of R^a ;





at least two occurrences of R^c ; or

at least one occurrence of R^a and at least one occurrence of R^c ; and

at least one occurrence of R^a and/or R^c differs from the other occurrences; and

wherein the compound is not:





1314. The compound of claim 1213, wherein at least one of R^1 , R^2 , and R^3 is substituted or unsubstituted (C_2 - C_{10})haloalkyl.

1415. The compound of claim 12-13 or 1314, wherein at least one of alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclyl, or heterocyclylalkyl is substituted with one or more substituents selected from $-R^a$, $-OR^a$, $-SR^a$, -

$N(R^a)_2$, $-N(R^a)_3^+$, $=NR^a$, $-NHC(=O)R^c$, $-C(=O)R^c$, $-C(=O)N(R^a)_2$, $-S(=O)_2R^c$, $-OS(=O)_2OR^a$, $-S(=O)_2OR^a$, $-S(=O)_2N(R^a)_2$, $-S(=O)R^c$, $-OP(=O)(OR^a)_2$, $-(alkylene)-C(=O)R^c$, $-C(=S)R^c$, $-C(=O)OR^a$, $-(alkylene)-C(=O)OR^a$, $-C(=S)OR^a$, $-C(=O)SR^a$, $-C(=S)SR^a$, $-(alkylene)-C(=O)N(R^a)_2$, $-C(=S)N(R^a)_2$, and $-C(-NR^a)N(R^a)_2$; and

~~at least one occurrence of R^a or~~ and R^c is are each independently heterocyclalkyl, cycloalkyl, or cycloalkylalkyl~~(cycloalkyl)alkyl~~.

~~1516.~~ The compound of any one of claims ~~1213-1415~~, wherein:

R^1 , R^2 , and R^3 are each independently H or substituted or unsubstituted alkyl, arylalkyl, or heterocyclalkyl;

R^4 , independently for each occurrence, is selected from substituted or unsubstituted alkyl, oxo, hydroxyl, $-OR^b$, hydroxyalkyl, $-CH_2OR^b$, and halo;

R^b is substituted or unsubstituted alkyl, aryl, arylalkyl, or heterocyclalkyl;

R^6 is hydrogen or substituted or unsubstituted alkyl; and

R^7 , R^8 , and R^9 are each independently hydrogen or alkyl.

~~1617.~~ The compound of any one of claims ~~1213-1516~~, wherein, where indicated, alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclalkyl, or heterocyclalkyl is unsubstituted or is substituted with one or more substituents selected from halo, haloalkyl, oxo, $-CN$, $-NO_2$, $=N-OH$, $-N_3$, $-R^a$, $-OR^a$, $-SR^a$, $-N(R^a)_2$, $-N(R^a)_3^+$, $=NR^a$, $-NHC(=O)R^c$, $-C(=O)R^c$, $-C(=O)N(R^a)_2$, $-S(=O)_2R^c$, $-OS(=O)_2OR^a$, $-S(=O)_2OR^a$, $-S(=O)_2N(R^a)_2$, $-S(=O)R^c$, $-OP(=O)(OR^a)_2$, $-(alkylene)-C(=O)R^c$, $-C(=S)R^c$, $-C(=O)OR^a$, $-(alkylene)-C(=O)OR^a$, $-C(=S)OR^a$, $-C(=O)SR^a$, $-C(=S)SR^a$, $-(alkylene)-C(=O)N(R^a)_2$, $-C(=S)N(R^a)_2$, and $-C(-NR^a)N(R^a)_2$; and


R^a , independently for each occurrence, is hydrogen, or substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclalkyl, heterocyclalkyl, cycloalkyl, or cycloalkylalkyl~~(cycloalkyl)alkyl~~; and



R^c , independently for each occurrence, is substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclalkyl, heterocyclalkyl, cycloalkyl, or cycloalkylalkyl~~(cycloalkyl)alkyl~~.


1718. The compound of any one of claims 1213-1617, wherein, where indicated, alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclyl, or heterocyclalkyl is unsubstituted or is substituted with one or more substituents selected from halo, haloalkyl, oxo, -R^a, -OR^a, -N(R^a)₂, -N(R^a)₃⁺, -NHC(=O)R^c, -C(=O)R^c, -C(=O)N(R^a)₂, -C(=O)OR^a, -(alkylene)-C(=O)OR^a, and -(alkylene)-C(=O)N(R^a)₂; and

R^a, independently for each occurrence, is hydrogen, or substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclyl, heterocyclalkyl, cycloalkyl, or cycloalkylalkyl(cycloalkyl)alkyl; and


R^c, independently for each occurrence, is substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclyl, heterocyclalkyl, cycloalkyl, or cycloalkylalkyl(cycloalkyl)alkyl.

1819. The compound of any one of claims 1213-1718, wherein R¹ is selected from ,





and/or p is 1 or 2; and R⁴, independently for each occurrence, is selected from -CH₃, halo, hydroxyl, hydroxyalkyl, and oxo; and/or




R⁷ is (C₁-C₁₀)alkyl; and/or

R⁸ is -CH₃ or -H; and/or

R⁹ is -CH₃ or -H.

~~19~~20. The compound of claim ~~12~~13, wherein the compound is:



, or a pharmaceutically acceptable salt thereof.

~~20~~21. The compound of claim ~~12~~13, wherein the compound is a peptide having an amino acid sequence represented by HyP-Gly-Gln-Xaa-Gly-Leu-Ala-Gly-Pro-Lys;

or a pharmaceutically acceptable salt and/or stereoisomer thereof;

wherein Xaa is selected from Glu, Asn, Gln, His, Lys, Ser, Thr, Ala, Val, Ile, Leu, Phe, Tyr, Trp, homo-Ser, Asp(Me), and Asn(Me); and

at least one amino acid residue in the peptide is a D-amino acid residue; or

the compound is a peptide having an amino acid sequence represented by HyP-Gly-Gln-Asp-Xaa-Leu-Ala-Gly-Pro-Lys;

or a pharmaceutically acceptable salt and/or stereoisomer thereof;

wherein Xaa is selected from Val, Ile, Leu, Ala, Phe, Tyr, Trp, Ser, Thr, and (N-Me)Gly; and

at least one amino acid residue in the peptide is a D-amino acid residue; or

the compound is a peptide having an amino acid sequence represented by HyP-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Xaa;

or a pharmaceutically acceptable salt and/or stereoisomer thereof;


wherein Xaa is selected from Tyr, Leu, Glu, Gln, Ala, and Nle(6-OH); and

at least one amino acid residue in the peptide is a D-amino acid residue; or

the compound is a peptide having an amino acid sequence represented by Xaa-Gly-Gln-Leu-Gly-Leu-Ala-Gly-Pro-Lys;

or a pharmaceutically acceptable salt and/or stereoisomer thereof;


wherein Xaa is selected from:



at least one amino acid residue in the peptide is a D-amino acid residue.

~~2422~~. The compound of claim ~~2021~~, wherein at least two, at least three, at least four, at least five, at least six, or at least seven amino acid residues in the peptide are D-amino acid residues.

~~2223.~~ A compound having the following structure:



Hyp
(2S,4R)

Gly

Gln

Leu

Gly

Leu

Ala

Gly


Pro

Lys(Ac)

; or a pharmaceutically

acceptable salt thereof.

~~23.~~ A compound represented by Formula (V):



~~or a pharmaceutically acceptable salt thereof;~~

~~wherein:~~

~~R¹ and R² are each independently H or substituted or unsubstituted alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclyl, or heterocyclylalkyl;~~

~~R⁴, independently for each occurrence, is selected from substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclyl, oxo, —OR^b, —CH₂OR^b, halo, hydroxyl, and hydroxyalkyl;~~


~~R^b is substituted or unsubstituted alkyl, aryl, arylalkyl, or heterocyclyl;~~

~~p is 0, 1, or 2;~~


~~R⁶ is hydrogen or substituted or unsubstituted alkyl; and~~

~~R⁹ is hydrogen or alkyl;~~


~~wherein the compound is not:~~



24. ~~The compound of claim 23, selected from the following:~~



25. ~~A compound represented by Formula (VI):~~



— or a pharmaceutically acceptable salt thereof;

— wherein:

— R^1 and R^2 are each independently H or substituted or unsubstituted alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclyl, or heterocyclalkyl

R^4 , independently for each occurrence, is selected from substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclyl, oxo, OR^b , CH_2OR^b , halo, hydroxyl, and hydroxyalkyl;

R^b is substituted or unsubstituted alkyl, aryl, arylalkyl, or heterocyclyl;


p is 0, 1, or 2;

R^6 is hydrogen or substituted or unsubstituted alkyl;


R^7 is hydrogen or alkyl; and

R^9 is hydrogen or alkyl;

wherein the compound is not:



26. — A compound represented by Formula (VII):



— or a pharmaceutically acceptable salt thereof;

— wherein:

— R^1 and R^2 are each independently H or substituted or unsubstituted alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclyl, or heterocyclylalkyl;

R^4 , independently for each occurrence, is selected from substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclyl, oxo, OR^b , CH_2OR^b , halo, hydroxyl, and hydroxyalkyl;

R^b is substituted or unsubstituted alkyl, aryl, arylalkyl, or heterocyclyl;



p is 0, 1, or 2;

R^6 is hydrogen or substituted or unsubstituted alkyl;


R^7 is hydrogen or alkyl; and

R^9 is hydrogen or alkyl;

wherein the compound is not:



27. — A compound represented by Formula (IX):



or a pharmaceutically acceptable salt thereof;

— wherein:

— R^1 and R^2 are each independently H or substituted or unsubstituted alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclyl, or heterocyclalkyl;

R^4 , independently for each occurrence, is selected from substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclyl, oxo, $-OR^b$, $-CH_2OR^b$, halo, hydroxyl, and hydroxyalkyl;

R^b is substituted or unsubstituted alkyl, aryl, arylalkyl, or heterocyclyl;

p is 0, 1, or 2;


R^6 is hydrogen or substituted or unsubstituted alkyl;

R^7 , R^8 , and R^9 are each independently hydrogen or alkyl;

J is OH or $-NR^*R^y$; and

R^* and R^y are each independently selected from H, optionally substituted alkyl, optionally substituted alkoxyalkyl, or R^* and R^y taken together with the intervening nitrogen atom form a ring.

28. — A compound represented by Formula (X-am):



— or a pharmaceutically acceptable salt thereof;

— wherein:

— R^1 , R^2 , and R^3 are each independently H or substituted or unsubstituted alkyl, alkoxy, haloalkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroalkyl, cycloalkyl, heterocyclyl, or heterocyclalkyl;

R^4 , independently for each occurrence, is selected from substituted or unsubstituted alkyl, aryl, arylalkyl, heterocyclyl, oxo, $-OR^b$, $-CH_2OR^b$, halo, hydroxyl, and hydroxyalkyl;

R^b is substituted or unsubstituted alkyl, aryl, arylalkyl, or heterocyclyl;

p is 0, 1, or 2;


R^6 is hydrogen or substituted or unsubstituted alkyl;

R^7 , R^8 , and R^9 are each independently hydrogen or alkyl;

J is OH or $-NR^*R^y$; and


~~R^x and R^y are each independently selected from H, optionally substituted alkyl, optionally substituted alkoxyalkyl, or R^x and R^y taken together with the intervening nitrogen atom form a ring.~~

~~2924.~~ A composition comprising a salt of a compound represented by Formula 8:



[Formula 8]; or

represented by Formula 10:









[Formula 10]; and,







wherein at least 90% of the compound in the composition is present as the salt.





~~3025.~~ A pharmaceutical composition comprising a salt composition of ~~any one of claims 1, 15-19, and/or 29-34~~ or a compound of any one of claims ~~12-13, 16-19~~20, and ~~22-23~~28 and a pharmaceutically acceptable carrier.

~~3126.~~ The pharmaceutical composition of claim ~~3025~~, wherein the pharmaceutical composition is formulated for topical administration to the eye, e.g., as eye drops.

~~3227.~~ Use of a composition comprising a the salt of any one of claims 1, 7-11, and 29, or the compound of any one of claims 12, 19, and 22-28, or the pharmaceutical composition of any one of claims 30-34 a compound selected from the following table:

<u>YDE-001</u>	 <p>Hyp Gly Gln Glu Gly Leu Ala Gly Pro Lys</p> <p>(2<i>S</i>,4<i>R</i>)</p>
<u>YDE-008</u>	 <p>Hyp Gly Gln Ala Gly Leu Ala Gly Pro Lys</p> <p>(2<i>S</i>,4<i>R</i>)</p>
<u>YDE-011</u>	 <p>Hyp Gly Gln Leu Gly Leu Ala Gly Pro Lys</p> <p>(2<i>S</i>,4<i>R</i>)</p>
<u>YDE-015</u>	 <p>Hyp Gly Gln Asp Val Leu Ala Gly Pro Lys</p> <p>(2<i>S</i>,4<i>R</i>)</p>
<u>YDE-016</u>	 <p>Hyp Gly Gln Asp Ile Leu Ala Gly Pro Lys</p> <p>(2<i>S</i>,4<i>R</i>)</p>
<u>YDE-023</u>	 <p>Hyp Gly Gln Asp Ser Leu Ala Gly Pro Lys</p> <p>(2<i>S</i>,4<i>R</i>)</p>

<u>YDE-026</u>	 <p>Hyp Gly Gln Homo-Ser Gly Leu Ala Gly Pro Lys</p> <p>(2S,4R)</p>
<u>YDE-038</u>	 <p>(4-hydroxyMe)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys</p> <p>(2S,4R)</p>
<u>YDE-044</u>	 <p>(4-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys</p>
<u>YDE-045</u>	 <p>(5-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys</p>
<u>YDE-048</u>	 <p>Hyp Ala Gln Leu Gly Leu Ala Gly Pro Lys</p>
<u>YDE-049</u>	 <p>Hyp Gly Ala Leu Gly Leu Ala Gly Pro Lys</p>

<u>YDE-054</u>	 <p>Hyp Gly Gln Leu Gly Leu Ala Ala Pro Lys</p>
<u>YDE-057</u>	 <p>D-Hyp (2R,4S) Gly Gln Leu Gly Leu Ala Gly Pro Lys</p>
<u>YDE-058</u>	 <p>D-Hyp (2R,4S) Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys</p>
<u>YDE-060</u>	 <p>D-Hyp (2R,4R) Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys</p>

in the manufacture of a medicament for the treatment of an eye disease;

wherein at least 90% of the compound in the composition is present as the salt.

3328. The use of claim 3227, wherein the eye disease is selected from retinopathy, keratitis, dry-macular degeneration, wet-macular degeneration, dry eye syndrome, heratoconjunctivitis sicca and keratoconjunctival epithelium disorder.